Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Guardant Health’s 10-K can feel like wading through both biotech jargon and accounting footnotes. Key details on liquid biopsy test volumes, FDA submissions, and R&D burn rates are scattered across hundreds of pages, while Form 4 insider sales from the founders often appear without context. If you have ever searched “Guardant Health SEC filings explained simply” or asked, “Where can I find the Guardant Health quarterly earnings report 10-Q filing?”, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate dense cancer-genomics language into clear insights, flagging segment revenue shifts and clinical milestone disclosures in seconds. Need real-time alerts? The moment a “Guardant Health Form 4 insider transactions real-time” filing hits EDGAR, we surface it alongside easy-to-read charts of executive stock transactions. Drill into any document:
- Guardant Health annual report 10-K simplified – spot test-volume growth and cash runway.
- Guardant Health quarterly earnings report 10-Q filing – track sequential margin changes.
- Guardant Health 8-K material events explained – catch trial results or reimbursement wins.
- Guardant Health proxy statement executive compensation – review R&D-weighted incentive plans.
Whether you’re modeling future oncology revenues or monitoring “Guardant Health earnings report filing analysis” for competitive intelligence, Stock Titan provides AI guidance that saves hours. Join institutional investors who are already “understanding Guardant Health SEC documents with AI” to make informed decisions faster.
Director Tariq Musa of Guardant Health reported multiple transactions on June 18, 2025:
- Sale: Disposed of 3,213 shares of common stock at $49.47 per share, retaining 7,190 shares after the transaction
- Stock Options: Received 6,833 stock options with exercise price of $50.57, expiring June 18, 2035
- RSUs: Granted 4,203 restricted stock units
Both the stock options and RSUs vest in full on the earlier of June 18, 2026, or the date of the next annual stockholders meeting. This filing represents standard equity compensation for a board member, with a simultaneous sale of existing shares. The transaction was executed through an attorney-in-fact, John G. Saia.
Guardant Health Director Myrtle S. Potter reported multiple securities transactions on June 18, 2025:
- Disposed of 26 shares of Common Stock at $49.47 per share, retaining direct ownership of 18,154 shares
- Acquired new stock options for 6,833 shares with exercise price of $50.57, expiring June 18, 2035
- Received 4,203 Restricted Stock Units (RSUs) at $0 cost basis
Both the stock options and RSUs vest in full on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs earlier. The transactions were reported through Form 4 filing, with attorney John G. Saia signing on Potter's behalf on June 20, 2025.
Guardant Health director Roberto Mignone received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis
Both grants feature a one-year vesting schedule, becoming fully vested on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be standard director remuneration, filed as required under SEC Section 16(a) regulations. The filing was completed by John G. Saia as attorney-in-fact for Mignone on June 20, 2025.
Guardant Health Director Steve E. Krognes received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57 per share, exercisable until June 18, 2035
- Restricted Stock Units (RSUs): 4,203 RSUs at zero cost basis
Both grants feature a one-year cliff vesting schedule, maturing on either June 18, 2025, or the date of the next annual stockholders meeting, whichever occurs first. The compensation package appears to be part of standard director compensation. The filing was submitted by John Saia as attorney-in-fact for Krognes on June 20, 2025.
Guardant Health Director Meghan V. Joyce received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: 6,833 options to purchase common stock at an exercise price of $50.57, fully vesting after one year on June 18, 2026 (or next annual stockholders meeting if earlier). The options expire on June 18, 2035.
- Restricted Stock Units (RSUs): 4,203 RSUs granted at $0 exercise price, with the same one-year vesting schedule as the stock options.
This Form 4 filing, signed by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combination of options and RSUs aligns the director's interests with shareholders while providing both upside potential through options and guaranteed value through RSUs, subject to vesting requirements.
Director Manuel Hidalgo Medina of Guardant Health [GH] received new equity compensation grants on June 18, 2025, consisting of:
- Stock Options: Granted 6,833 options to buy common stock at an exercise price of $50.57, which vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first. The options expire on June 18, 2035.
- Restricted Stock Units (RSUs): Awarded 4,203 RSUs that vest fully on June 18, 2026 or the next annual stockholders meeting, whichever occurs first.
This Form 4 filing, submitted by attorney-in-fact John G. Saia on June 20, 2025, represents standard director compensation equity grants. The combined awards suggest continued board engagement and alignment with shareholder interests through both performance-based options and time-vested RSUs.
Guardant Health director Vijaya Gadde received new equity compensation grants on June 18, 2025, consisting of:
- Stock options to purchase 6,833 shares of common stock at an exercise price of $50.57 per share, expiring June 18, 2035
- 4,203 Restricted Stock Units (RSUs) with no exercise price
Both the stock options and RSUs will fully vest on the earlier of: (1) the one-year anniversary of the grant date (June 18, 2025) or (2) the date of the next annual stockholders meeting. This equity compensation package appears to be part of standard director compensation. The Form 4 was filed by John G. Saia as attorney-in-fact for Vijaya Gadde on June 20, 2025.
Guardant Health Director Ian T. Clark reported multiple securities transactions on June 17-18, 2025:
- Disposed of 6,672 shares of common stock at an average price of $48.38 per share from the Thornton-Clark Family Trust
- Received a new stock option grant for 6,833 shares with exercise price of $50.57, vesting in full on June 18, 2025 or next annual stockholders meeting
- Granted 5,092 restricted stock units (RSUs) vesting in full on June 18, 2025 or next annual stockholders meeting
Following these transactions, Clark retains 9,851 shares indirectly through the family trust, plus the new equity awards. The stock sale was executed in multiple transactions within a $0.03 price range.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
What is Guardant Health's primary business focus?
How do Guardant Health's liquid biopsy tests work?
What types of diagnostic assays does Guardant Health offer?
How does Guardant Health differentiate itself from competitors?
What role does data analytics play in Guardant Health’s operations?
Who are the primary users of Guardant Health's products?
What are the benefits of using a liquid biopsy?
How does Guardant Health contribute to advancements in cancer research?
